news
-
21 May 2018Immunocore wins Large Business of the Year at the 2018 Vale4Business Awards
Immunocore Limited, a leading T Cell Receptor (TCR) biotechnology company, is pleased to note that the Company was the winner of the 2018 Vale4Business (V4B) Award for Large Business of the Year.
The V4B Awards aim to bring together the achievements of businesses in the area; recognising, rewarding and promoting our local success stories.
Immunocore joined a prestigious list of winners at this year’s awards, including Oxford Space Systems and CIS Ltd, at the awards ceremony at the Williams F1 Conference Centre in Grove.
Andrew Hotchkiss, Chief Executive Officer of Immunocore, said: “We are delighted to have been presented with this award, which reflects the great progress we have made in growing our business but also developing our ImmTAC (Immune mobilising monoclonal TCRs Against Cancer) technology. We’re particularly pleased to have been chosen among such strong competition in this region, which is such a great hub for dynamic businesses like Immunocore. The unique combination of factors which have helped nurture so many businesses in the Oxford region have played a key role in Immunocore’s success and we’re proud to be a standard-bearer for the area.
“I would like to thank the rest of the team at Immunocore for their invaluable hard work, commitment and support.”
Simon Bassett, lead partner from Oxfordshire based law firm and lead sponsors, Royds Withy King, said: “Our firm has been a long-time supporter of the Vale4Business team and we were delighted to present Immunocore with Large Business of the Year Award.
“As a Sunday Times Top 100 firm with pride in supporting our communities and helping businesses to get ahead, we were impressed by Immunocore’s growth, their commitment to engaging their employees and to public engagement and outreach with their many STEM ambassadors.”
Related
Immunocore Announces Leadership Change
Immunocore Appoints Andrew Hotchkiss as Chief Commercial Officer
Immunocore and MEPC announce significant laboratory expansion at Milton Park in Oxfordshire, UK
Immunocore Announces Third Oncology Target Selected in Discovery Collaboration with GlaxoSmithKline
Immunocore identifies second novel ImmTAC® in the GSK collaboration
Immunocore wins Financing Deal of the Year at the 12th Annual SCRIP Awards 2016
Immunocore Appoints Paul Fry as Chief Financial Officer
Immunocore Ranked in the Sunday Times Hiscox Tech Track 100
Immunocore Wins Private UK Life Science Company of the Year at Biotech and Money Assembly and Awards
Immunocore’s IMCgp100 Starts Phase I Trial for the Treatment of Uveal Melanoma
Immunocore’s IMCgp100 Granted Orphan Drug Designation by US FDA for the Treatment of Uveal Melanoma
Immunocore Starts Clinical Trial with IMCgp100 in Combination with MedImmune Immunotherapies Durvalumab and Tremelimumab
Immunocore and GlaxoSmithKline Select First ImmTAC Clinical Candidate in Discovery Collaboration
Immunocore expands its senior management team and opens US Office
Immunocore wins Biotech of the Year at the SCRIP Awards 2015